Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Biocartis forum geopend
Volgen
Bron: DeTijd Analisten reageren opgelucht op het nieuws dat Biocartis BCART zijn (weliswaar verlaagde) jaardoelstellingen heeft behaald. Het aantal geïnstalleerde Idylla-minilabo's steeg met 337 stuks naar 1.310 terwijl de doelstelling lag op een aangroei van 325 tot 350 stuks. De cijfers wijzen op een prille pick-up van Idylla in de Verenigde Staten, signaleert KBC Securities . 'Dit cijfer wijst op marktinteresse voor het product. We geloven dat Biocartis in de VS een slechte timing koos voor de lancering van Idylla, veeleer dan dat het product niet concurrentieel zou zijn', klinkt een hoopvolle Guy Sips, die zijn koopadvies herhaalt bij een koersdoel van 13,50 euro. Ook de kaspositie van 179 miljoen euro lag boven de doelstelling tussen 170 en 175 miljoen euro. 'Dat is een bemoedigend resultaat, maar Biocartis is er nog niet', zegt het beurshuis Kepler Cheuvreux . 'Er zal nog meer nodig zijn om het vertrouwen te herstellen.' Kepler herhaalt zijn koopadvies met een koersdoel van 11 euro. 'We nemen aan dat de ramp-up in de VS nu echt vertrokken is', klinkt het bij Degroof Petercam . 'Dit volume geeft ons vertrouwen in de langetermijnvooruitzichten van het bedrijf', zegt analist Thomas Guillot die het aandeel onder review plaatst.
Via bank al belegd in een korf,1ste maal dat ik me heb laten verleiden om zelf te beleggen, heb er vertrouwen in.
BL I agree that the differences in our numbers may very well be the source of the information on consoles and cartridges. I look at it as a quick and dirty confirmation that the system sales are resulting in increased usage of the platform. I may have pulled the numbers from an unaudited source. FL
Flatlander schreef op 9 januari 2020 18:32 :
BL
I agree that the differences in our numbers may very well be the source of the information on consoles and cartridges. I look at it as a quick and dirty confirmation that the system sales are resulting in increased usage of the platform. I may have pulled the numbers from an unaudited source.
FL
The differences are negligible and therefor unimportant. BL
I like tracking on a half year basis since we do not have that many data points. Either way the relative direction is the important point. This number could increase by a factor of 10 or more if the RUO designation can be replaced by clinical diagnostic approval in several world markets. I have put up several posts that suggest that the problems in the U.S. may be more of a problem with the regulatory framework than a problem with Idylla. Unfortunately the FDA is trying to apply the medical device approval process rather than a more appropriate genomic testing standard that the Obama administration proposed over a decade ago. The FDA 510K process generally emphasizes precedents and requires the manufacturer to compare results to existing equipment already on the market. In the case of Idylla this is tough since there are no similar IVD devices to compare its results to. Former commissioner Gotleib had changing the IVD approval process as a priority but for whatever reason, he decided to resign instead. FDA has internal guidance documents (see link below) but not comprehensive legislation from Congress. This is the reason I keep mentioning that BCART may have to be assertive to counter the lack of appropriate guidance from Congress. Here is an overview of the FDA process that BCART has to seek approval under. www.fda.gov/medical-devices/ivd-regul... Note that Idylla is likely bumping up against the De Novo classification (meaning no adequate precedent system exists for comparison). For this reason FDA might likely be requiring validation studies. It would seem that these are temporary hurdles, but none the less they hinder more rapid expansion of sales. FL
De visie van KBC Securities Ondanks het feit dat de groei van het aantal Idylla-installaties met 337 stuks onder de schatting van KBC Securities (350) ligt, gelooft analist Lenny Van Steenhuyse dat de belangstelling van de markt voor het product aanhoudt. Verder benadrukt hij dat Biocartis in de VS eerder kampt met 'timing issues' (langere overgangstijd van R&D-validatievolumes naar commerciële volumes) dan dat er een structureel concurrentieel probleem is. De cartridgevolumes vertoonden in het vierde kwartaal een sterk herstel, wat KBCS ziet als een indicatie van herstel in de Amerikaanse markt vanaf de eerste helft van 2019. Met een volumegroei van 24% in de eerste helft van 2019 en 27% in het derde kwartaal van 2019, vertaalt dit zich naar een groei van 37% in de tweede jaarhelft. Aangezien de herziene doelstellingen van Biocartis voor de eerste helft van 2019 destijds ingegeven waren door de teleurstellende prestaties in de VS, gelooft KBCS dat de groei van 25-30% wordt gedragen door de Europese regio en de rest van de wereld (RoW) en dat een eventuele opwaartse trend vanaf dat moment kan worden toegeschreven aan de prestaties van de VS. Onze analist schat dan ook dat het herstel in het laatste kwartaal te danken is aan een stijgende omzet in de VS. Wat de cash betreft presteerde Biocartis in het vierde kwartaal beter dan KBCS had verwacht: de cash burn bedroeg 18 miljoen euro tegenover de prognose van 20,7 miljoen. Daardoor klokt de totale cash burn over het boekjaar 2019 op ongeveer 65 miljoen euro af. Zonder rekening te houden met investeringen voor een potentiële derde productielijn (die waarschijnlijk in 2021 zal worden opgezet), gelooft onze analist dat de cash burn dit jaar niet boven het niveau van 2019 zal uitkomen. Biocartis blijft als zodanig in een financieel comfortabele positie. Op 5 maart maakt het bedrijf zijn volledige jaarresultaten bekend. KBC Securities bevestigt het koersdoel van 13,5 euro voor de aandelen en het "Kopen"-advies.
Is het verder nog iemand opgevallen dat er in de eindveiling nog even voor zo'n 1 miljoen EUR aan stukken werd verhandeld? Dat was echt een aardig pakket hoor wat daar snel nog even over de toonbank heenging!
Flatlander schreef op 9 januari 2020 19:05 :
I like tracking on a half year basis since we do not have that many data points. Either way the relative direction is the important point. This number could increase by a factor of 10 or more if the RUO designation can be replaced by clinical diagnostic approval in several world markets.
I have put up several posts that suggest that the problems in the U.S. may be more of a problem with the regulatory framework than a problem with Idylla. Unfortunately the FDA is trying to apply the medical device approval process rather than a more appropriate genomic testing standard that the Obama administration proposed over a decade ago. The FDA 510K process generally emphasizes precedents and requires the manufacturer to compare results to existing equipment already on the market.
In the case of Idylla this is tough since there are no similar IVD devices to compare its results to . Former commissioner Gotleib had changing the IVD approval process as a priority but for whatever reason, he decided to resign instead. FDA has internal guidance documents (see link below) but not comprehensive legislation from Congress. This is the reason I keep mentioning that BCART may have to be assertive to counter the lack of appropriate guidance from Congress.
Here is an overview of the FDA process that BCART has to seek approval under.
www.fda.gov/medical-devices/ivd-regul... Note that Idylla is likely bumping up against the De Novo classification (meaning no adequate precedent system exists for comparison). For this reason FDA might likely be requiring validation studies. It would seem that these are temporary hurdles, but none the less they hinder more rapid expansion of sales.
FL
The absence of comparable IVD devices to compare results should never be a reason for the FDA to block or delay medical progress and innovation. I hope that the American partners of Biocartis can play a significant role in this regard towards the FDA. Sometimes the FDA looks like an old-fashioned, stuck institute in a modern world.
Flatlander schreef op 9 januari 2020 19:05 :
I like tracking on a half year basis since we do not have that many data points. Either way the relative direction is the important point. This number could increase by a factor of 10 or more if the RUO designation can be replaced by clinical diagnostic approval in several world markets.
I have put up several posts that suggest that the problems in the U.S. may be more of a problem with the regulatory framework than a problem with Idylla. Unfortunately the FDA is trying to apply the medical device approval process rather than a more appropriate genomic testing standard that the Obama administration proposed over a decade ago. The FDA 510K process generally emphasizes precedents and requires the manufacturer to compare results to existing equipment already on the market. In the case of Idylla this is tough since there are no similar IVD devices to compare its results to. Former commissioner Gotleib had changing the IVD approval process as a priority but for whatever reason, he decided to resign instead. FDA has internal guidance documents (see link below) but not comprehensive legislation from Congress. This is the reason I keep mentioning that BCART may have to be assertive to counter the lack of appropriate guidance from Congress.
Here is an overview of the FDA process that BCART has to seek approval under.
www.fda.gov/medical-devices/ivd-regul... Note that Idylla is likely bumping up against the De Novo classification (meaning no adequate precedent system exists for comparison). For this reason FDA might likely be requiring validation studies. It would seem that these are temporary hurdles, but none the less they hinder more rapid expansion of sales.
FL
FL I track quite a few tech companies in the States. Many of them have a P/S ratio (ttm) upwards of 10, some even go as far as 30 or above. These companies are of course high growth names but many of them are also loss making. Remember that Biocartis, just as it is now, also has an annual sales growth upwards of 30%!! I estimate that FY19 it is trading at a P/S of 8.5, so that is quite reasonable for such a growth company. Of course I agree an acceleration in console growth would be welcome, but with the current console sales growth of around 330 units per year, and with a sustained cartridge sale of around 160 (80 per half year) per console, the overall cartridge sales increase would already be a very respectable 39.71% YonY according to my model. Imagine what an acceleration in either of the aforementioned variables would do! But my point is that even without an acceleration the stock is not overpriced and the growth still very impressive. BL
While BCART was up on 6 times ave volume it closed on the low of the day. I hope Verrelst generates some enthusiasm at JP Morgan. It would be nice to move decisively from the lows of this week! BL I agree wholeheartedly that BCART is priced relatively cheaply for the current growth and especially for the potential future growth. My point was that the U.S. MDx market was becoming decidedly frothy. EXAS at a $15B market cap seems very expensive to me. Since so much of their potential worldwide growth in OncoTypeDx is dependent on Idylla, I'd much rather be in BCART since it would benefit from the launch of the same content throughout the world. Furthermore, I like platform companies. As long as partners keep stepping up to launch on Idylla they have a lot of shots on goal to accelerate from what is already very enviable growth. Much of the US market is invested passively thru ETFs. I think they are damping the kind of volatility that would have shaken weaker hands out of the market. This is likely leading to overvaluation in some areas of the U.S markets. Earnings in the S&P were flat in 2019 yet the S&P Index was up 29%. I don't think you can pull that rabbit out of the hat too many years in a row. I'd much rather be investing in BCART despite the fact that it is far below the radar of most worldwide funds. The relative value difference convinced me to add to my position on Wed. Regards FL
Reply schreef op 9 januari 2020 21:16 :
Is het verder nog iemand opgevallen dat er in de eindveiling nog even voor zo'n 1 miljoen EUR aan stukken werd verhandeld?
Dat was echt een aardig pakket hoor wat daar snel nog even over de toonbank heenging!
Dat was mij ook opgevallen ja. Wat ik intussen ook heb opgemerkt, op de IR website van Biocartis wordt Sycomore niet langer vermeld als aandeelhouder. Daar zal spoedig ook wel een officiele transparantieverklaring voor komen. investors.biocartis.com/en/shareholders Bovendien viel het mij ook op dat de aandelen die door mijn broker werden uitgeleend intussen niet langer zijn uitgeleend. Ik ben er dus vrij zeker van dat de shorters intussen de aandelen van Sycomore hebben opgekocht om hun short positie af te bouwen. Dan nog een laatste ding, de totale short positie op woensdag bedroeg zo'n 3.5% terwijl de aandelen van Sycomore op dat moment al onder de 2.9% zaten. Naast de aandelen van Sycomore zullen de shorters dus ook nog andere aandelen moeten opkopen als ze hun positie volledig naar 0 willen krijgen.
Sinds gisteren ingestapt in biocartis, opening price 6.15 met in de bid bedragen tot €7.00. goeiemorgen iedereen :D
[Modbreak IEX: Gelieve hier geen IEX Premium content te plaatsen, een aantal berichten is bij dezen verwijderd.]
Onderstaande RTL-Z Beurs Inside video is van einde 2018, net voor de spreekwoordelijke "hobbel in de weg" voor Biocartis in 2019. Ondertussen weten we dat deze "hobbel in de weg" in Q4 2019 weer keurig is geplaveid door Biocartis en dat er momenteel weer vol gas gegeven kan worden. Vervang in de video Fisher Scientific door het eigen Biocartis salesteam en weet dat de financiering van Biocartis ondertussen in 2019 op orde is gebracht. Dan resteert een enthousiaste "pitch" met een zeer positieve kijk op de toekomst voor Biocartis vanaf 2020.www.youtube.com/watch?v=_ApN7bgSLBk
Reply Wish I spoke Dutch! The tone sounded positive. I have a couple random thoughts. I wish I knew the specific reasoning of Sycamore, JnJ, RM and DeBioPharm reducing or eliminating their stakes in BCART. DeBioPharm is a major investor in Immunexpress and much of their involvement with BCART seems to date back to the earliest stages of the Septicyte collaboration. RM appears to have sold in conjunction with his resignation from the Board. There appears to be a shift toward a more American based shareholder base. Invesco (formerly Oppenheimer), DFA have excellent reputations in small cap investments. I'm not overly concerned, but just like some sense of the motivation factors of fellow shareholders. Did the sellers take the H1 2019 numbers presented in September as more than a hiccup that it now appears to be? Trading action in BCART looks good today. I was hoping to see such follow thru confirmation after the short term profit taking at the end of yesterdays session.. Have a Good Weekend. FL
I'm not certain how the board translations are conducted but I notice that some words get changed to the point that they are nonsensical. "earliest internships or" Was initially typed as "earliest initiation of" I saw something in one of my previous posts about "be a hero" that I have no Idea how it was included in the post. All in all, we are still fortunate to live in an age when we have tools to overcome language differences to converse across the Atlantic. Unfortunately, Americans as a whole are much less bilingual, trilingual ...than our European counterparts. FL
Reply The fact that the FDA approval process is the same as surgical instruments and the like rather that the specific MDx regulations that were proposed a decade ago is a testament to political dysfunction. You can probably sense my frustration with the issue. I'm sure FDA is also frustrated. That is why I keep stressing the fact that others have resorted to lawsuits when they felt they were at an impasse. Funny thing is that our politicians from both parties grandstand about why the costs of health care in the U.S. are about twice that of other developed markets. Passing common sense legislation would go along ways toward bringing life improving products to the consumer. Regards FL
Flatlander schreef op 10 januari 2020 17:27 :
Reply
The fact that the FDA approval process is the same as surgical instruments and the like rather that the specific MDx regulations that were proposed a decade ago is a testament to political dysfunction. You can probably sense my frustration with the issue. I'm sure FDA is also frustrated. That is why I keep stressing the fact that others have resorted to lawsuits when they felt they were at an impasse.
Funny thing is that our politicians from both parties grandstand about why the costs of health care in the U.S. are about twice that of other developed markets. Passing common sense legislation would go along ways toward bringing life improving products to the consumer.
Regards FL
FL As I said before. I hope that the American partners of Biocartis can play a significant role in this regard towards the FDA and frustration for all parties in the regulation process can be reduced to a minimum. Have a Good Weekend
Flatlander schreef op 10 januari 2020 15:44 :
Reply
Wish I spoke Dutch! The tone sounded positive.
I have a couple random thoughts.
I wish I knew the specific reasoning of Sycamore, JnJ, RM and DeBioPharm reducing or eliminating their stakes in BCART. DeBioPharm is a major investor in Immunexpress and much of their involvement with BCART seems to date back to the earliest stages of the Septicyte collaboration. RM appears to have sold in conjunction with his resignation from the Board. There appears to be a shift toward a more American based shareholder base. Invesco (formerly Oppenheimer), DFA have excellent reputations in small cap investments. I'm not overly concerned, but just like some sense of the motivation factors of fellow shareholders. Did the sellers take the H1 2019 numbers presented in September as more than a hiccup that it now appears to be?
Trading action in BCART looks good today. I was hoping to see such follow thru confirmation after the short term profit taking at the end of yesterdays session..
Have a Good Weekend.
FL
FL, I really would put these concerns to bed. Sycomore is an investment company and they probably saw better investment opportunities in the short run elsewhere, who knows. The DeBiopharm sale dates from May 23!!! (and was reported only in October), so well before the profit warning of September 5. RMM sale dates from 2018 even. The events are thus completely unrelated. The reason for the JNJ sale may well be that they bought the convertible with the aim of selling some shares later on. They probably stuck to that plan. Invesco even added to their position in 2019! There are a number of reasons why someone would buy or sell shares. The same applies to companies I suppose. BL
Flatlander schreef op 9 januari 2020 23:41 :
BL
I agree wholeheartedly that BCART is priced relatively cheaply for the current growth and especially for the potential future growth. My point was that the U.S. MDx market was becoming decidedly frothy. EXAS at a $15B market cap seems very expensive to me. Since so much of their potential worldwide growth in OncoTypeDx is dependent on Idylla, I'd much rather be in BCART since it would benefit from the launch of the same content throughout the world. Furthermore, I like platform companies. As long as partners keep stepping up to launch on Idylla they have a lot of shots on goal to accelerate from what is already very enviable growth.
Much of the US market is invested passively thru ETFs. I think they are damping the kind of volatility that would have shaken weaker hands out of the market. This is likely leading to overvaluation in some areas of the U.S markets. Earnings in the S&P were flat in 2019 yet the S&P Index was up 29%. I don't think you can pull that rabbit out of the hat too many years in a row. I'd much rather be investing in BCART despite the fact that it is far below the radar of most worldwide funds. The relative value difference convinced me to add to my position on Wed.
Regards FL
FL, As far as the overall market is concerned, as long as the FED and other central banks keep pumping money into the system, or should I say the stock market, every connection with the real economy will be lost. Concerning Bcart, indeed in my opinion too the stock is priced relatively cheaply for the current growth and especially for the potential future growth. I remember, after the September 5 profit warning, an analyst already said the price drop to 7.5 was overdone. So I think the stock price will return to that "more normal" level before long. Let's wait and see. I am also looking forward to the JP Morgan presentation of next week. Possible another positive surprise will be awaiting. Have a nice weekend, BL
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee